These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 2641116)

  • 1. [Efficacy and tolerance of dipivephrin].
    Sellem E; Cottier F; Chigot D
    Ophtalmologie; 1989; 3(3):223-4. PubMed ID: 2641116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of 0.1% dipivalyl epinephrine and 1% epinephrine in patients with glaucoma or ocular hypertension].
    Shao H; Sun XY; Bai FG
    Zhonghua Yan Ke Za Zhi; 1994 Mar; 30(2):104-7. PubMed ID: 8001439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dipivefrin: its mechanism of action, clinical efficacy and good tolerance].
    Harper DG; Novack GD; Borrmann LR; Branin MJ
    Ophtalmologie; 1989; 3(4):306-7. PubMed ID: 2641142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and tolerability of dipivefrin in the treatment of primary intraocular hypertension].
    Sellem EA; Cottier F; Maugery J
    Bull Soc Ophtalmol Fr; 1987 May; 87(5):675-6, 679-80. PubMed ID: 3621416
    [No Abstract]   [Full Text] [Related]  

  • 5. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension.
    Ito K; Goto R; Matsunaga K; Sugimoto K; Uji Y
    Jpn J Ophthalmol; 2004; 48(3):276-80. PubMed ID: 15175922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
    Titouamane S; Baudouin C
    J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
    Magacho L; Reis R; Shetty RK; Santos LC; Avila MP
    Ophthalmology; 2006 Mar; 113(3):442-5. PubMed ID: 16458964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients.
    Day DG; Sharpe ED; Atkinson MJ; Stewart JA; Stewart WC
    Eye (Lond); 2006 May; 20(5):583-90. PubMed ID: 15933751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
    Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
    J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of three kinds of anti-glaucoma eyedrops on ocular blood flow].
    Zhao J; Mao J; Sui R
    Zhonghua Yan Ke Za Zhi; 2000 Nov; 36(6):425-30. PubMed ID: 11853641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
    Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
    Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylsalicylic acid does not reduce the intraocular pressure variation in ocular hypertension or glaucoma.
    Lindén C; Alm A
    Exp Eye Res; 2000 Mar; 70(3):281-3. PubMed ID: 10712814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-sensitivity testing with scanning-laser ophthalmoscope stimulation in normal, ocular hypertensive, and glaucomatous patients.
    Horn F; Budde W; Korth M
    Ger J Ophthalmol; 1996 Nov; 5(6):428-34. PubMed ID: 9479531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The visual evoked potential in glaucoma and ocular hypertension: effects of check size, field size, and stimulation rate.
    Towle VL; Moskowitz A; Sokol S; Schwartz B
    Invest Ophthalmol Vis Sci; 1983 Feb; 24(2):175-83. PubMed ID: 6826322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Episcleral venous pressure in primary glaucoma, ocular hypertension and in patients with hypertension].
    Viazigina LV; Batmanov IuE
    Vestn Oftalmol; 1985; 101(3):12-4. PubMed ID: 4035858
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
    Shi JM; Jiang YQ
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans.
    Gandolfi SA; Vecchi M
    Invest Ophthalmol Vis Sci; 1996 Mar; 37(4):684-8. PubMed ID: 8595970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France].
    Bron A; Nordmann JP; Baudouin C; Rouland JF; Kadi A; Sartral M
    J Fr Ophtalmol; 2003 Nov; 26(9):895-903. PubMed ID: 14631273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.